Jazz Pharmaceuticals plc Revenue 2009–2025
Jazz Pharmaceuticals plc reported $4.27B of revenue for fiscal 2025. That was 4.9% higher than fiscal 2024. Compared with fiscal 2020, the change was +80.6%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $4.27B | +4.9% |
| FY 2024 | $4.07B | +6.1% |
| FY 2023 | $3.83B | +4.8% |
| FY 2022 | $3.66B | +18.3% |
| FY 2021 | $3.09B | +30.9% |
| FY 2020 | $2.36B | +9.3% |
| FY 2019 | $2.16B | +14.3% |
| FY 2018 | $1.89B | +16.8% |
| FY 2017 | $1.62B | +8.8% |
| FY 2016 | $1.49B | +12.3% |
| FY 2015 | $1.32B | +13.0% |
| FY 2014 | $1.17B | +34.4% |
| FY 2013 | $872.42M | +48.9% |
| FY 2012 | $585.98M | +115.2% |
| FY 2011 | $272.28M | +56.7% |
| FY 2010 | $173.78M | +35.3% |
| FY 2009 | $128.45M | — |
Source: Jazz Pharmaceuticals plc SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open JAZZ 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Jazz Pharmaceuticals plc reported $4.27B of revenue for fiscal 2025. That was 4.9% higher than fiscal 2024. Compared with fiscal 2020, the change was +80.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Jazz Pharmaceuticals plc
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeJazz Pharmaceuticals plc — frequently asked questions
What is Jazz Pharmaceuticals plc's revenue?
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $4.27B for fiscal year 2025, per its SEC filings.
How has Jazz Pharmaceuticals plc's revenue changed over time?
Between fiscal 2009 and 2025, JAZZ's revenue grew at roughly 24.5% per year (compound annual rate), from $128.45M to $4.27B.
Where does this data come from?
Figures are computed from Jazz Pharmaceuticals plc's official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.